Abbisko Cayman shares jump 7.9% on positive clinical trial results
Shares of Abbisko Cayman jump 7.9% to HK$8.95, their biggest one-day percentage gain since June 29, after the company announced positive preliminary efficacy results from a Phase II clinical trial of its achondroplasia drug. The stock hit HK$8.95, its highest level since September 9.